Secondary objectives were to compare the detection rates of the clinical investigators for both radiopharmaceuticals in a patient-based analysis; to assess the diagnostic performance of both radiotracers for PCa lesions in a region-based analysis; to assess the impact on diagnostic thinking, therapeutic decision making, and adequacy of therapy changes for both radiotracers; and to assess the safety profile of 18F-PSMA-1007. The gene discussed is FOLH1; the disease is posterior cortical atrophy.